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Abstract
The aqueous extract of Anemarrhena asphodeloides (BN108) induces apoptosis in various cancer cell lines but is significantly
less cytotoxic in non-transformed cells. Chemical fractionation of BN108 showed that its cytotoxicity is associated with
timosaponins, steroidal saponins of coprostane type. Timosaponin BII (TBII) is a major saponin in BN108, but it shows little
cytotoxicity. A much less abundant TAIII induces cell death in tumor cells but not in normal cells, reproducing the selectivity
of the total extract BN108. Glycosidase treatment, by removing the extra sugar moiety in TBII, converts it to TAIII and confers
cytotoxic activity. Analysis of the mechanisms of death induced by TAIII revealed activation of two distinct pro-apoptotic
pathways: first, inhibition of mTORC1 manifested in much reduced phosphorylation of mTORC1 targets; second, induction
of endoplasmic reticulum stress culminating in phosphorylation of eIF2a and activation of caspase 4. These pro-apoptotic
pathways are activated by TAIII selectively in tumor cells but not in normal cells. Both pathways play a causative role in TAIII
cytotoxicity, as restoration of either mTOR activity or relief of ER stress alone offer only partial protection from TAIII.
Inhibition of mTORC1 and induction of ER stress apparently contribute to the induction of the previously reported
autophagic response in TAIII-treated cells. TAIII induced autophagy plays a protective role in TAIII induced death signaling,
and failure to mount autophagic response is associated with heightened sensitivity to TAIII induced apoptosis. The multiple
death-promoting and apparently tumor-selective responses to TAIII, its ability to inhibit mTORC1, and the possibility of
further enhancing its cytotoxicity by pharmacological inhibition of autophagy, make TAIII an attractive candidate for
development as a cancer therapeutic agent.
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Introduction
This work describes the anti-tumor activity of the aqueous
extract from the plant Anemarrhena asphodeloides (BN108), and one of
the timosaponins present in the extract, TAIII [1]. BN108
contains a number of timosaponins [1–3], and a variety of
biological effects have been attributed to these compounds. TAIII
was recently reported to induce apoptosis and protective
autophagy in HeLa cells [4]. However, the mechanism through
which TAIII induces cell death remains unclear.
Induction of apoptosis is a prominent mode of cytotoxic action
of many chemotherapeutic drugs. Some of them induce apoptosis
through a mitochondrial pathway, but some, most notably the
proteasome inhibitors, induce cell death via endoplasmic reticu-
lum (ER) stress mediated apoptotic pathway. ER stress is elicited
by a wide variety of conditions including nutrient deprivation,
impaired protein degradation or secretion, calcium imbalance and
many others. ER stress involves specific transcriptional and
translational responses that are largely controlled by three ER
resident sensor proteins: IRE1, ATF6, and PERK (reviewed in
[5,6]). Activated PERK phosphorylates eukaryotic translation
initiation factor eIF2a, resulting in the general inhibition of
protein synthesis, but paradoxically induces a specific increase in
translation of transcription factor ATF4. ATF4, in turn, induces
increases in levels of several protein chaperons. Phosphorylation of
eIF2a is central in the integrated stress response, named so
because it is activated by diverse stressful conditions. Sustained or
severe ER stress leads to activation of caspases, in particular
caspase-4, followed by apoptosis [7].
ER stress was found recently in several independent studies to
have an unanticipated consequence: induction of autophagy
(reviewed in [8,9]). Autophagy is a conserved cellular pathway
that serves to degrade bulk cytoplasmic material ([10,11]). It is
activated in response to nutrient and energy starvation, and after
treatment with some chemotherapeutic drugs. Autophagy plays a
positive role in preservation of energy and nutrients, and also
contributes to degradation of misfolded proteins when this
function of ER is disabled due to stress. Autophagy can play a
protective role in cell survival, but often serves as a mechanism of
programmed cell death (reviewed in [12]).
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nutrients, ATP and growth factors are in adequate supply) by a
conserved cellular pathway centered on the Ser/Thr kinase target
of rapamycin (mTOR) (reviewed in [13]). mTORC1 regulates
efficiency of protein translation and promotes cell growth
(reviewed in [14,15]). The two essential direct targets of mTORC1
activity are the 70 kDa ribosomal protein S6 kinase, and the
eukaryotic translation initiation factor 4E binding protein 1
(4eBP1). Phosphorylation of these proteins by mTORC1 serves
to activate and sustain protein translation and is used as a read-out
for mTORC1 activity. Inhibition of mTORC1 has profound
negative consequences for protein translation and cell growth, and
at the same time activates autophagy. Another mTOR containing
complex, mTORC2, promotes cell signaling through phosphor-
ylation and activation of the pro-survival and pro-proliferative
kinase Akt [16]. mTOR kinase in the mTORC2 complex is
thought to be not sensitive to inhibition by rapamycin [17,18], but
inhibitors of mTOR kinase domain have been developed that
suppress activity of mTOR in both mTORC complexes [19,20].
The possible effect of mTORC2 on autophagy remains to be
investigated.
This study was prompted by our observations that BN108
induced cell death selectively in a variety of cancer cell lines, but
not in several immortalized non-transformed lines examined. We
have therefore attempted to define the active compounds in
BN108 and study their mechanism of action through examination
of the mode of cell death and analysis of the effects on gene and
protein expression. Timosaponin AIII was identified as a major
selective cytotoxic activity in BN108, and its selective cytotoxic
activity involves inhibition of mTOR, induction of ER stress and
protective autophagy.
Materials and Methods
Reagents and antibodies
Chloroquine and EGF were purchased from Sigma. Caspase
activity substrates, AnnexinV- Alexa 488 conjugate and Vibrant
Lipid Raft labeling kit were purchased from Molecular Probes/
InVitrogen. Caspase inhibitors were purchased from EMD
Biosciences, TAIII from Wako Pure Chemical Industries, TBII
and sarsasapogenin from AAPIN Chemicals, UK. Antibodies to
Bim, phosphorylated and total S6 ribosomal protein, phosphoAkt
S473, Akt, phospho4eBP1 and 4eBP1, phosphoeIF2a and eIF2a
were from Cell Signaling Technology, ATP-citrate lyase from
Epitomics, Id1 and Id3 from Biocheck; REDD1/DDIT4 and
IDI1 from Protein Tech Group; SREBP-2 from BD Biosciences,
INSIG-1 from Biovision, PARP from Zymed, MYC, GRP78 and
GAPDH from Santa Cruz Biotechnology.
Cell culture and treatments
All cell lines were obtained from the ATCC, and propagated
according to the instructions provided. BN108 tea-like extract for
use in cell culture was prepared in water as described above and
freeze-dried. The resulting powder was weighed, dissolved in
water to 50 mg/ml (dry weight per volume) and sterile-filtered.
Timosaponins were dissolved in DMSO at 100 mM. Cells were
treated with BN108 at a concentration of 0.5 mg/ml and with
TAIII as indicated or with corresponding solvent (water or
DMSO, labeled as ‘‘untreated’’ throughout the paper).
Flow cytometry
For apoptosis determination cells were collected by trypsiniza-
tion into their culture media, washed with PBS and stained with
Annexin V- Alexa Fluor 488 (InVitrogen) and propidium iodide
(PI), and analyzed immediately after 15 minute incubation using
the CellQuest software on the FACScan (Becton Dickinson). All
Annexin V-binding cells were considered to be apoptotic. Cell
cycle analysis was performed with the ethanol fixed cells stained
with PI in PBS at 20 mg/ml. Caspase activity assays were
performed with the Vibrant FAM caspase assay kit (InVitrogen)
according to the manufacturer’s instructions.
Activity Guided Isolation of Anti-cancer Compounds from
BN108
BN108 extract was prepared by adding water to the ground
dried herb (10:1, volume : mass), then bringing the mixture to a
boil. The herbal solution was allowed to simmer for 45–60
minutes, then suction filtered (Whatman 1 paper filter) to produce
the crude tea. The crude tea was partitioned with an equal volume
of ethyl acetate (repeated once) and the organic layers were
recovered, combined and concentrated. Cytotoxic activity of the
partitions was determined using CyQuant assay (Promega), which
detected significant activity in the recovered organic layers. The
concentrated ethyl acetate layers were subjected to open column
chromatography on silica gel with hexane:ethyl acetate and ethyl
acetate:methanol gradients. Active fractions were again deter-
mined by CyQuant assay and eluted from the silica column in the
middle of the ethyl acetate:methanol gradient. LC/MS analysis of
the active fractions identified a mixture of terpene sugar
conjugates including timosaponin AIII, timosaponin BII, and
several other uncharacterized saponins.
LC-MS/MS Analysis of TAIII and TBII concentrations in
BN108
Timosaponins were quantified using a triple quadrupole,
API4000 LC/MS system (Sciex./Applied Biosystems, Foster City,
CA) in negative MRM (multiple reaction monitory) mode with
Collision Activated Dissociation (CAD) gas. The first quadrupole
was set to select the deprotonated molecular ion [M–H]
2 of TAIII
(m/z 739) and TBII (m/z 921). The second quadrupole was used as
collision chamber, and the third quadrupole to select the
characteristic product ions of both compounds (m/z 577 for
TAIII and m/z 759 for TBII). Peak area ratios obtained from
MRM mode of the mass transitions for TAIII (m/z 739 R 577)
and TBII (m/z 921 R 759) were used for quantification.
Western blot analysis
Whole cell lysates were electrophoresed on SDS-PAGE and
transferred to nitrocellulose membranes. Membranes were blotted
with antibodies at recommended concentrations overnight at 4uC
and the bound primary antibodies were detected using peroxidase-
conjugated secondary antibodies. Blots were developed using
SuperSignal enhanced chemiluminescence kit (Pierce) and imaged
on Kodak Imager ISR2000.
Timosaponin BII de-glycosylation
Laminarinase (Sigma L5272) was dissolved to a final concen-
tration of 1 unit/ml in reaction buffer (120 mM sodium acetate
pH 5.0, 60 mM NaCl and 40% DMSO) Timosaponin BII at final
concentration of 1 mM was added to enzyme mix and incubated
for 30 min. at 50uC. Sample was then heated for 5 min. at 90uCt o
deactivate the enzyme. Mass-spectrometric analysis of the
digestion products was conducted on TOF LC/MS 6210, Agilent.
Mass-spectromeric analysis of cellular proteins
MDAMB231 cells were treated with TAIII for 4, 8, and
16 hours or left untreated. Cells were disrupted in lysis buffer
Cytotoxic Selectivity of TAIII
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and 100 mg protein was denatured with 8 M urea and 100 mM
TEAB pH 8.5 in the presence of 5 mM TCEP (reducing agent) for
2 hrs at room temperature. Cysteine residues were blocked with
50 mM iodoacetamide for 1 hr at room temperature in a final
volume of 30 ml. Sample was diluted to 0.5 ml with 100 mM
TEAB, 0.5 mM CaCl2 and then concentrated on an YM-3
Microcon (Millipore). Trypsin (Promega) was added and protein
was digested for 12 hrs at 37uC. Proteins were then labeled with
iTRAQ labeling reagents 114, 115, 116 or 117 (Applied
Biosystems). The sample was mixed with iTRAQ reagent and
ethanol (final 70%) and incubated for 1 hr at room temp. The
reaction was quenched by adding an equal volume of water and
incubation for 30 min. Sample was dried by spin-vap and
resuspended in 0.1% formic acid for a final concentration of
1 mg/ml protein. Mass spectrometry analysis was performed on
an Agilent 6500 Q-TOF LC/MS with Chip Cube. Identification
of peptides and quantitation of iTRAQ labeling was done with
SpectrumMill software (Agilent).
Lentivirus - mediated siRNA expression and DNA
transfection
For REDD1 silencing, siRNA constructs in the LKO plasmid
vector were purchased from Open Biosystems/Thermo. Viruses
were produced in HEK293 cells according to manufacturer’s
instructions and used to transduce cells, followed by selection in
pre-determined concentration of puromycin. Human Grp78
cDNA in pCMV-ICIS expression plasmid was obtained from
Openbiosystem. The plasmid was co-transfected with pCDNA3-
Neo at 20:1 ratio into MDA-MB231 cells, followed by selection in
G418 and by limited dilution cloning of high GRP78 expressing
clones.
Results
The aqueous extract of Anemarrhena asphodeloides
Bunge (BN108) induces apoptotic cell death in many
cancer cell lines but not in non-transformed cells
Previous work has shown that BN108 has a strong growth
inhibitory effect in a number of human cancer cell lines [21].
Several cancer and normal cell lines were analyzed for their
responses to BN108 using Annexin V/propidium iodide (PI)
staining to determine if BN108 induces apoptotic cell death. At the
concentration of 0.5 mg/ml BN108 induced appearance of
Annexin V binding cells, both PI-negative (early apoptotic) and
PI positive (late apoptotic) in many of the cancer cell lines tested,
but not in the non-transformed lines of mammary epithelium or in
primary fibroblasts (Figure 1A). Breast cancer cell lines but not the
non-transformed cells treated with BN108 also showed apoptotic
DNA fragmentation (Figure 1B).
To verify the apoptotic nature of cell death induced by BN108,
we have examined caspase activation in breast cancer cell line
BT474 and primary fibroblasts IMR90 as well as immortalized
mammary epithelium MCF10A. First, we found that proteolysis of
PARP1 known to be mediated by caspases occurred in BT474
cells but not in MCF10A (Figure 1C) or IMR90 cells (not shown).
Next, caspase activation in BT474 cells but not in normal cells
treated by BN108 was confirmed by FACS-based assay of caspase
activity (Figure 1D). Possible roles of specific caspases in apoptosis
induced by BN108 were then examined using relevant inhibitors
and substrates. Among different caspase inhibitors used, the
caspase-4 inhibitor z-LEVD-FMK and, to a lesser degree, caspase-
9 inhibitor z-LEHD-FMK, were effective in diminishing the
numbers of apoptotic cells, while inhibition of caspase-3 and 6 had
much less effect (Figure 1E and not shown). Direct caspase activity
assays also showed specific involvement of caspases 4- and-9
(Figure S1). Involvement of caspases 4 and 9 strongly indicates that
cell death induced by BN108 could involve endoplasmic reticulum
stress [7].
Structure-activity relationship between timosaponins
from BN108
In order to isolate the tumor-selective cytotoxic activity from
BN108, we have performed chemical fractionations of the extract.
Activity-guided isolation of active fractions from BN108 consistently
showed that cytotoxic activity co-purifies with timosaponins, of
which several were identified previously in the extracts of
Anemarrhena asphodeloides [1,2]. We have therefore examined if two
of BN108 timosaponins,TAIII andTBII, aswell asTAIII aglycone,
sarsasapogenin (Figure 2A) are selectively cytotoxic to cancer cells,
similarly to BN108. We have found that TAIII induced significant
cell death in cancer cell lines BT474 and MDAMB231 at
micromolar concentrations (Figure 2A). Non-transformed
MCF10A cells were relatively resistant to TAIII at the range of
concentrations tested (Figure 2A), and so were primary fibroblasts
IMR90 (not shown). This selective cytotoxicity of TAIII to cancer
cells recapitulates the selectivity of the total extract BN108. In
addition, TAIII-induced cell death, similar to BN108, was partially
suppressed in presence of caspase-4 inhibitor (Figure 1D) but was
much less affected by the inhibition of caspase-3 and -6 (not shown).
Timosaponin TBII and sarsasapogenin had no appreciable
cytotoxic activity in any of the tested cell lines at concentrations of
up to 50 mM (not shown and Figure 2C).
We have quantified the concentration of timosaponins in
BN108 using LC-MS/MS. The amount of TAIII was found to be
2.1560.09 mg/gram dry weight of the herb, and TBII
79.1162.01 mg/g. Therefore, the concentrations of timosaponins
in the culture media containing 0.5 mg/ml BN108 (routinely used
in cytotoxicity assays) amount to 1.5 mM of TAIII and 37 mMo f
TBII in the BN108 treatment media. The concentration of TAIII
in BN108 is therefore just somewhat lower than the 2.5 mMo f
TAIII shown to induce cell death in about 50% of treated BT474
cells (Figure 2A). This indicates that the TAIII is a major cytotoxic
component of BN108, though it is possible and even likely that the
extract contains additional cytotoxic substances such as other
timosaponins identified previously [2].
The steroid cores of timosaponins AIII and BII are identical,
but TBII contains an extra sugar moiety in addition to a shared
disaccharide moiety (Figure 2B). We have therefore attempted to
determine if this sugar is responsible for the lack of the cytotoxic
activity of TBII. Several glycosidases were tested for their ability to
cleave TBII, and laminarinase was found to convert TBII into
TAIII as determined by LC/MS analysis. Laminarinase treated
preparations of TBII became cytotoxic towards two breast cancer
cell lines (Figure 2C) but not to MCF10A cells, similar to TAIII
(not shown). We conclude that the extra sugar present in TBII
interferes with its potential cytotoxicity. Enzymatic removal of this
sugar moiety converts TBII to TAIII and unmasks its cytotoxicity.
It will be of interest to determine if TBII could be cleaved in vivo by
glycosidases (in particular, from intestinal microflora) to produce
TAIII, thus strongly enhancing the anti-tumor activity of BN108
considering the relatively high TBII content in the extract.
Analysis of the changes in gene expression induced by
BN108 and TAIII
To try and discern the pathways involved in cell death induction
by BN108, expression array analysis (Methods S1) was performed
Cytotoxic Selectivity of TAIII
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treatment with BN108. Only 41 transcripts were found to be
upregulated more than two-fold in BT474 cells treated with
BN108, and even fewer were downregulated two-fold or more
(Table S1). Several genes with known anti-proliferative and/or
pro-apoptotic activities were induced: REDD1/DDIT4, p21CIP,
stratifin, cyclin G2, GDF15. A prominent group of BN108
induced genes represented enzymes involved in biosynthesis of
cholesterol.
Among the downregulated genes with known functions were
several transcripts coding for secreted proteins: amphiregulin,
CYR61, thrombospondin, CXCL12, VEGF-C, as well as the pro-
proliferative genes MYC and cyclin D1.
Because TAIII is at least partially responsible for the apoptosis-
inducing activity of BN108, we have conducted further expression
array analysis with three cell lines that showed different sensitivities
to TAIII and BN108: BT474, somewhat less sensitive
MDAMB231 and the relatively resistant nontransformed cell line
MCF10A. TAIII treatment affected levels of many more mRNAs
than BN108; but majority of transcriptional changes induced by
BN108 in BT474 were also induced by TAIII. Thus, out of 42
genes upregulated by BN108 more than two-fold, 28 (i.e., two
thirds) were also upregulated by TAIII. This strongly indicates that
many of the cellular responses to BN108 are induced by its active
constituent TAIII.
Comparisons of TAIII induced transcriptional changes between
the three cell lines analyzed showed significant overlaps between
BT474 and MDAMB231 (Table S2). However, the magnitudes of
changes in RNA abundance were frequently different. In
particular, induction of genes in the cholesterol biosynthesis
pathway was significantly muted in MDAMB231 cells compared
to BT474 (Table 1). On the other hand, MDAMB231 cells treated
Figure 1. Aqueous extract from Anemarrhena asphodels induces apoptosis selectively in cancer cells. A. The indicated cell lines (three
breast carcinoma lines; three prostate carcinoma lines, three immortalized mammary epithelial lines) and primary fibroblasts IMR90 were treated with
0.5 mg/ml of BN108 for 24 hours. Cells were analyzed for apoptosis by flow cytometry of Annexin V/PI stained cells. Percentage of Annexin V-
binding cells is shown; results are an average of at least three experiments. B. Cell cycle analysis of BT474 and MCF10A cells treated with 0.5 mg/ml
BN108 for 48 hours. Numbers show percentages of cells with DNA content less than 2n. C. Western blot analysis of PARP cleavage in BT474 and
normal MCF10A cells treated with BN108 for 24 hours. D. BT474 and IMR90 cells were treated for 1 or 2 days with BN108, fixed, and cells with
activated caspases were identified by flow cytometry with the Vibrant FAM caspase assay kit (InVitrogen). E. Apoptotic cells were detected in BT474
cultures as described in 1A. Cells were treated for 24 hours with BN108 (0.5 mg/ml) or TAIII (2.5 mM) with or without caspase 4 inhibitor LEVD-fmk or
caspase 3 inhibitor DEVD-fmk at 10 mM.
doi:10.1371/journal.pone.0007283.g001
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of genes with functions in ER stress response and amino acid
starvation, most of which were only weakly induced in BT474
(Table 2). In the non-transformed MCF10A cells the genes whose
expression was significantly changed after TAIII treatment were
mostly distinct from transcripts affected in cancer cell lines (Table
S2), which could reflect the resistance of MCF10A to apoptosis
induction by TAIII. The discernible commonalities between
MCF10A transcriptional response to TAIII and that of breast
cancer cell lines were a weak induction in the former of expression
of some genes in the cholesterol biosynthesis pathway, ER stress
response and induction of autophagy (Table 2).
In breast cancer cells BN108 and TAIII induced changes in
expression of several genes with known functions in apoptosis,
which were verified by Western blotting. Expression of REDD1/
DDIT4, p21CIP, stratifin and GDF15 proteins was increased
during the treatment; while expression of Myc, Id1 and Id3 was
decreased (some of these changes are shown in Figure 3A). These
proteins were not affected in MCF10A cells. In addition, TAIII
induces higher levels of pro-apoptotic protein Bim in BT474 cells
but not in MCF10A cells (Figure 3A). Similar changes were
observed in MDAMB231 and in prostate carcinoma Du145 (not
shown) indicating the possible role of these expression changes in
the selective anti-tumor activity of TAIII.
BN108 and TAIII downregulate the activity of mTORC1
We have examined the potential consequences of the observed
increases in levels of REDD1 in BN108 and TAIII treated cancer
cells. REDD1/DDIT4 is a stress-responsive gene [22,23] that has
been characterized as a strong inhibitor of mTORC1 pathway
[24–26]. Indeed, the phosphorylation of mTOR on serine 2448
and phosphorylation of mTORC1 downstream targets 4eBP1 and
S6 ribosomal protein were inhibited in BT474 treated with either
BN108 or TAIII, as well as in MDAMB231 cells (not shown), but
not in MCF10A (Figure 3B).
To examine if REDD1 plays a role in the observed inhibition of
mTORC1 by TAIII, expression of lentivirus-based siRNA for
REDD1 was introduced into MDAMB231 and BT474 cells.
REDD1 level in untreated cells was significantly reduced, and
induction of REDD1 by TAIII was also adversely affected
(Figure 4A). However, neither BT474 nor MDAMB231 cells with
reduced REDD1 expression were protected from killing by TAIII
(not shown). Moreover, phosphorylation of the downstream targets
of mTORC1, 4eBP1 and S6 ribosomal protein was not restored in
Figure 2. TAIII is the selectively cytotoxic compound in BN108 extract. A. Three cell lines indicated were treated with a range of
concentrations of TAIII for 24 hours, and cell viability was analyzed by Annexin-PI staining. B. Structures of TAIII, TBII and sarsasapogenin. C. Cells lines
were treated for 24 hours with TBII at 40 mM, heat–inactivated laminarinase alone (0.5 mg/ml), or a mixture of both after incubation for 30 min at
50uC and heat-inactivation of the enzyme. MS analysis indicated that about 20 to 30% of TBIII was converted to TAIII. Apoptotic cells were identified
by Annexin V binding. The results are representative of the two separate experiments performed with very similar results.
doi:10.1371/journal.pone.0007283.g002
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BT474 MDAMB231 MCF10A
INSIG1 insulin induced gene 1 8.71 6.14 1.84
SC4MOL sterol-C4-methyl oxidase-like 7.64 2.07 1.35
LPIN1 lipin 1 6.69 2.31 2.22
SC4MOL sterol-C4-methyl oxidase-like 6.10 2.08 1.24
HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7 5.10 1.33 1.54
HSD17B7P2 hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2 4.73 0.98 1.10
IDI1 isopentenyl-diphosphate delta isomerase 1 4.50 1.80 1.19
MVD mevalonate (diphospho) decarboxylase 3.95 1.20 1.39
GNE glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase 3.83 1.49 0.98
LDLR low density lipoprotein receptor (familial hypercholesterolemia) 3.54 2.37 1.70
SQLE squalene epoxidase 3.32 1.05 1.27
PGM2L1 phosphoglucomutase 2-like 1 3.30 1.65 1.59
ACSS2 acyl-CoA synthetase short-chain family member 2 3.24 1.38 1.55
DHCR7 7-dehydrocholesterol reductase 3.11 1.47 1.48
FDFT1 farnesyl-diphosphate farnesyltransferase 1 2.38 1.24 1.12
doi:10.1371/journal.pone.0007283.t001
Table 2. Partial list of genes related to ER stress and autophagy that are upregulated in TAIII-treated cells.
ER stress related transcripts BT4747 MDAMB231 MCF10A
ATF3 activating transcription factor 3 4.48 13.42 3.30
CTH cystathionase (cystathionine gamma-lyase) 1.30 8.24 2.83
CTH cystathionase (cystathionine gamma-lyase) 1.25 6.02 1.61
LRF chromosome 5 open reading frame 41 6.28 5.44 2.74
CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 0.74 5.21 1.39
DDIT3 DNA-damage-inducible transcript 3/CHOP 0.81 4.68 1.40
HERPUD1 homocysteine-, endoplasmic reticulum stress-inducible 1.35 4.65 1.25
ASNS asparagine synthetase 1.09 4.38 2.12
TRIB3 tribbles homolog 3 (Drosophila) 0.71 4.12 1.89
SLC38A2 solute carrier family 38, member 2 1.94 3.20 1.82
SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 1.01 3.05 0.70
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A/GADD34 1.46 3.01 3.53
SLC3A2 solute carrier family 3 (activators of dibasic and neutral amino acid transport) 0.95 2.93 2.19
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 0.73 2.87 0.83
GLS glutaminase 1.16 2.75 3.21
NDRG1 N-myc downstream regulated gene 1 2.00 2.69 3.65
SLC16A3 solute carrier family 16, member 3 (monocarboxylic acid transporter 4) 0.91 2.41 1.26
XBP1 X-box binding protein 1 0.57 2.33 1.88
SLC1A4 solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 0.73 2.3 3.42
HSPA6 heat shock 70 kDa protein 6 (HSP70B9) 2.53 1.17 2.26
EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3/PERK 2.17 1.29 1.76
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.16 1.77 1.23
Autophagy- related transcripts
ULK1 unc-51-like kinase 1 (C. elegans) 1.61 4.80 3.47
SQSTM1 sequestosome 1 1.87 3.51 1.69
MAP1LC3B microtubule-associated protein 1 light chain 3 beta 1.89 2.66 1.44
doi:10.1371/journal.pone.0007283.t002
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of REDD1 might not be the primary cause for the inhibition of
mTORC1 activity by TAIII.
Activity of mTORC1 is regulated by many cellular pathways
and players other than REDD1, one of the most prominent being
the AKT kinase [16,27]. We have therefore examined if activity of
AKT is affected by BN108 and TAIII and found that
phosphorylation of AKT is indeed reduced by both treatments
in cancer cells but not in MCF10A cells (Figure 4B). mTORC2
phosphorylates the serine 473 of Akt leading to its activation,
raising a possibility that activity of mTORC2 is also affected by
TAIII.
BT474 cells contain highly amplified and overexpressed
HER2 gene, while MDAMB231 have high levels of EGFR that
contribute to Akt activation. We then examined if exogenous
stimulation of oncogenic receptor tyrosine kinases by a growth
factor might sustain the activity of Akt and mTORC1 and
confer protection from TAIII. Treatment with TAIII in
presence of exogenous EGF indeed conferred a significant
protection to BT474 cells and less so to MDAMB231
(Figure 4B). Western blot analysis of cells co-treated with TAIII
and EGF revealed that in presence of EGF TAIII fails to elicit a
significant reduction in phosphorylation of Akt and mTORC1
targets in BT474 cells (Figure 4C). Examination of the
phosphorylation of mTOR itself in cells treated with TAIII in
absence or presence of EGF showed that phosphorylation of
mTOR on serine 2448 (characteristic of mTOR in mTORC1)
and on mTOR on serine 2481 (characteristic of activated
mTOR in mTORC2 [28]) are both reduced in TAIII treated
BT474 cells but restored in presence of EGF. However, it
should be noted that the protection conferred by EGF was only
partial, even in BT474 cells where phosphorylation of mTOR,
Akt and mTORC1 targets appeared to be effectively sustained
in presence of EGF (Figure 4C). This indicates that in addition
to the inhibition of mTORC1, TAIII might have other death-
promoting effects on tumor cells.
To identify the other potential cellular pathways contributing to
TAIII cytotoxicity in tumor cells, we examined the functional role
of Id-1 that, along with Id-3 is strongly downregulated in breast
cancer cells but not in MCF10A (Figure 3A and Table S2).
Exogenous Id-1 was stably expressed in MDAMB231 cells, and
higher levels of Id-1 were maintained during TAIII treatment (not
shown). However, analysis of Id-1 expressing cells showed that
enforced expression of Id-1 levels did not confer an improved
survival during TAIII treatment (not shown), indicating that
downregulation of Id-1 by TAIII could be consequences of TAIII
effects on cell viability or proliferation. Moreover, concomitant
downregulation of REDD1 and forced expression of Id-1 did not
improve survival of MDAMB231 cells treated with TAIII (not
shown).
Figure 3. TAIII and BN108 induce similar changes in gene expression and inhibit major proliferative signal transduction pathways
selectively in cancer cells. A. Both BN108 and TAIII induce expression of REDD1 and inhibit MYC in BT474 but not in MCF10A cells. Top panels, cell
extracts were prepared fro untreated cells and cells treated with BN108 (0.5 mg/ml) and TAIII (2.5 mM in BT474 and 7.5 mM for MCF10A) for 4 hours.
Bottom panels, time course of expression of the indicated proteins in BT474 and MCF10A cells treated with TAIII. B. Top, both BN108 and TAIII inhibit
phosphorylation of mTORC1 targets s6 ribosomal protein and 4eBP1 as well as AKT kinase selectively in cancer cells. Bottom, time course of inhibition
of activating posphorylations of AKT and mTOR, as well as inhibition of phosphorylation of mTORC1 targets s6 and 4eBP1by TAIII in BT474 cells.
doi:10.1371/journal.pone.0007283.g003
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The results described above show that inhibition of mTORC1
activity during TAIII treatment plays a significant but not
exclusive role in TAIII induced apoptosis. We have then turned
our attention to the potential significance of the observation that
ER stress is induced in cells treated with TAIII, as manifested by
expression of ER stress/amino acid starvation/integrated stress
response (ISR) markers (Table 2; partial list) and the activation of
caspase 4 (Figure 1D). Array expression analyses showed a robust
activation in MDAMB231 cells of the known ISR markers, such as
CHOP, TRIB3, HEPRUD, ASNS, and solute carriers, while
upregulation of some of these was weak or absent in BT474 and
MCF10A (Table 2). Interestingly, a gene described as LRF, a
negative regulator of unfolded protein response [29], was most
strongly induced in BT474 cells.
In order to verify that breast cancer cells indeed develop ER
stress response when treated with BN108 or TAIII, we have
examined phosphorylation of the translation initiation factor
eIF2a, considered to be a hallmark of ER stress response. We
found that eIF2a is phosphorylated in a time–dependent manner
in BT474 cells treated with BN108 (Figure 5A) but not in
MCF10A (not shown because no appreciable phosphorylation of
eIF2a was seen in MCF10A cells either before or after treatment).
Similarly, treatment with TAIII also induced phosphorylation of
eIF2a in BT474 and MDAMB231 cells even though the
maximum phosphorylation was seen in MDAMB231 cells soon
after the start of treatment, and in BT474 cells only at 16 hours
after treatment start (Figure 5B).
Of the three components of ER stress response, PERK is the only
one that phosphorylates eIF2a. We have therefore examined the
status of PERK in TAIII-treated cells, and found that PERK is
phosphorylated in MDAMB231 cells but not in BT474, in spite of
the fact that eIF2a is phosphorylated in both cell lines.
Transcription factor ATF4, a major target of induction by activated
eIF2a, was strongly induced in MDAMB231 cells and less so in
BT474 cells indicating that the processes downstream of eIF2a
phosphorylation are intact in both cell lines but are more robust in
MDAMB231 cells. The expression array analysis did not show
upregulation of RNAs for classical ER stress responders such as
PDI, calreticulin and GRP78. To examine if TAIII induces a
predominantly translational ER stress response, we conducted a
proteomic analysis of MDAMB231 cells treated with TAIII for 4, 8
and 16 hours. PDI and calreticulin protein levels were increased in
a time-dependent manner, though the increases were relatively
modest(at16 hours,77%increase forcalreticulinand70% forPDI;
Table S3). We have examined possible changes in levels of GRP78
and other markers of ER stress in breast cancer cells treated with
TAIII,AninductioninlevelsofGRP78andTRIB3wasobservedin
MDAMB231 cells but not in BT474 cells (Figure 5B), indicating a
weak or possibly atypical ER stress response in the latter.
It has been reported that proteolytic activation of the master
regulator of cholesterol biosynthesis SREBP-2 [30] and increased
expression of its target genes are observed in cells subjected to ER
stress [31–34]. Expression array analyses indicated upregulation of
a number of SREBP-2 target genes in TAIII treated cells (Table 1
and Tables S1 and S2). We have confirmed by Western blot
Figure 4. EGF treatment but not silencing of REDD1 provides a partial protective effect against TAIII cytotoxicity. A. Levels of REDD1
and phosphorylation of s6 protein in MDAMB231 cells transduced with control (231-vec) or REDD1 siRNA expressing lentivirus (231-REDD1KD). Cell
extracts were analyzed by Western blotting before and 4 hours after treatment with 5 mM of TAIII. B. Effect of addition of exogenous EGF on survival
of BT474 and MDAMB231 cells treated with TAIII for 24 hours (4 mM for BT474 and 7.5 mM for MM231). C. Effect of exogenous EGF on Akt activity,
mTORC1 activity and mTOR phosphorylation in cells treated with TAIII for 16 hours. Western blotting was done with the phospho-specific antibodies
and antibodies detecting total levels of the indicated proteins.
doi:10.1371/journal.pone.0007283.g004
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with BN108 or TAIII (Figure S2), and that two of its
transcriptional targets isopentenyl-diphosphate delta isomerase
(IDI1) and ATP citrate-lyase (ACL), identified in the expression
array experiments, are induced in MDAMB231 (not shown),
BT474 and MCF10A cells (Figure S2). At the same time,
quantification of the cholesterol levels over 24 hours of treatment
showed only modest or no changes in cells treated with BN108 or
TAIII (Figure S2). This indicates that neither depletion of total
cellular cholesterol levels nor cholesterol overload are a likely
cause of cell death observed in breast cancer cell lines, in particular
because activation of SREBP-2 was also observed in the relatively
resistant MCF10A cells (Figure S2). Activation of transcription of
INSIG-1, a protein that negatively regulates activation of SREBP-
2 [35,36] could be relevant to the relatively modest increases in the
total cholesterol levels in TAIII treated cells (Figure S2). We
suggest that TAIII induces ER stress that is strongly manifested in
the effects on cholesterol biosynthetic pathway, in particular in
BT474 cells, but less so in the activation of the classical markers of
ER stress in these cells.
Induction of robust ER stress response can play a protective role
and prevent cell death. Chaperon GRP78, when overexpressed,
was shown to protect cells from ER stress induced apoptosis
[37,38]. Because induction of GRP78 by TAIII was not observed
in BT474 cells and was relatively modest in MDAMB231 cells, we
have examined if introduction of GRP78 expression (Figure 5C)
could protect the cells from killing by TAIII. Figure 5D shows that
expression of GRP78 in MDAMB231 cells indeed conferred a
significant degree of protection from apoptosis induced by TAIII,
as well as by proteasome inhibitor MG132, a known inducer of
ER stress and apoptosis. This supports our hypothesis that, in
addition to the mTOR inhibition, ER stress contributes to the
TAIII induced apoptosis.
TAIII induces protective autophagy
Expression array analysis detected induction by TAIII of three
transcripts directly related to autophagy: ULK1/ATG1, sequesto-
some, and MAP1LC3B (Table 2). These data further support the
previously published results that TAIII induces autophagy [4].
The TAIII-induced autophagy was shown to play a protective role
in TAIII induced death of HeLa cells [4].The possible role of
autophagy in cell death induced by TAIII in breast cancer cells
was therefore examined.
Treatment of cells with TAIII in presence of autophagy inhibitor
chloroquine revealed that autophagy plays different roles in TAIII
induced responses. In the most sensitive cells, BT474, inhibition of
autophagy did not affect the outcome of TAIII treatment, indicating
that autophagy is either not induced or is not protective in these cells.
However, inhibition of autophagy in MDAMB231 and particularly
in the MCF10A cells lead to a significantly increased cell death in
response to TAIII (Figure 6A). Autophagy also played a protective
role in the TAIII induced apoptosis in a breast cancer line SKBr3
and, as previously reported, HeLa cells (not shown). Induction of
autophagic responses was confirmed by following levels and
distribution of GFP-LC3 in transfected MDAMB231 cells after
treatment with TAIII, as well as Western blot analysis of LC3
cleavage (Figure S3). However, treatment of BT474 cells with TAIII
has not affected distribution of the transfected GFP-LC3 (not shown)
indicating that these cells do not develop autophagy in response to
TAIII. We conclude that the previously reported induction of
Figure 5. TAIII induces ER stress and protective autophagy. A. Treatment with BN108 induce phosphorylation of translation initiation factor
eIF2a. Cell extracts were prepared from BT474 cells treated with BN108 (0.5 mg/ml) for times indicated and subjected to gel electrophoresis and
blotting with antibodies against phosphorylated form of eIF2a (Ser51) or total eIF2a protein. B. Western blot analysis of the expression of some
markers of ER stress in MDAMB231 and BT474 cells. Cells were treated with TAIII for the indicated times and after electrophoresis extract were
immunobloted with indicated antibodies. C. Western blot analysis of MDAMB231 cells transfected with control or GRP78 expressing vector. D.
Expression of exogenous GRP78 in MDAMB231 cells offers partial protection against apoptosis induced by TAIII (5 mM) or MG132 (0.25 mM).
doi:10.1371/journal.pone.0007283.g005
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TAIII-resistant cells, and that lack of autophagic response to TAIII is
associated with increased sensitivity to its pro-apoptotic effects.
Discussion
This work describes the selective anti-tumor activity of BN108,
an herbal extract used in Traditional Chinese Medicine (TCM),
and identifies its major cytotoxic chemical component, TAIII.
This conclusion is based on several lines of evidence: TAIII
demonstrates the same selectivity towards breast cancer cell lines
as BN108; TAIII induces apoptosis involving caspase-4 activation
similar to BN108; TAIII induces transcriptional changes in breast
cancer cells that largely overlap with these induced by BN108;
both TAIII and BN108 inhibit mTORC1 in cancer cells and
induce protective autophagy. Another major and more abundant
timosaponin from BN108, TBII, could be enzymatically converted
to TAIII by the removal of extra sugar, which unmasks its
cytotoxicity. Since BN108, like most herbal extracts in TCM, is
taken orally, it will be of interest to determine if TBII could be
converted to active TAIII in vivo by glycosidases produced by
intestinal microflora.
Perhaps not surprisingly, we found that both TAIII and BN108
elicit several different cellular responses, some of which were
observed in all cells examined, and some that were selectively
activated in tumor cells but not in the more resistant normal cells
(Figure 6B). The interplay between cellular pathways that are
differentially activated or inhibited by TAIII in different cells
probably determines the fate of cells subjected to treatment. The
strong inhibitory effect of TAIII on activity of mTORC1 was
observed selectively in tumor cells. The mTORC1 is frequently
inappropriately activated in cancer and is contributing to the
transformed phenotype [15] , and this could play a role in the
increased sensitivity of certain cancer cells to TAIII . The precise
mechanism of mTORC1 inhibition by TAIII remains to be
determined, but it involves growth factor activated proliferative
pathways (Figure 4B) and does not involve depletion of energy
stores (ATP levels are not affected in cells treated with TAIII or
BN108; data not shown). Some transcription changes induced by
TAIII are indicative of amino acid starvation response (Table 2),
that could contribute to inhibition of mTORC1. In any case,
selective inhibition of mTORC1 and Akt in cancer cells versus
non-transformed cells is very likely to contribute to the selective
cytotoxicity of BN108 and TAIII.
mTORC1 is well known to keep autophagy in check [13], and
its inhibition could be a culprit in TAIII induced autophagy.
However, inhibition of mTORC1 by TAIII in BT474 cells
(Figure 3B) did not induce protective autophagy. One could
hypothesize that BT474 might simply harbor a defect in a gene
whose product plays a role in autophagy, but other cytotoxic
treatment do induce autophagic response in BT474 (data not
shown). At the same time, protective autophagy was induced by
TAIII in MCF10A cells, where mTORC1 was not inhibited. This
would indicate that TAIII could induce autophagy through
cellular pathways other than mTORC1 inhibition.
Indeed, we have identified a second cellular response elicited by
TAIII that could be a potent inducer of autophagy: ER stress,
manifested in the induction of a number of ER stress markers, and,
importantly, phosphorylation of eIF2a, the central node in the
integrated stress responses [5]. No eIF2a phosphorylation was
detected in MCF10A cells, even though they show some
transcriptional responses associated with ER stress (Table 2) and
activate cholesterol biosynthesis pathway (Figure S2).
Phosphorylation of eIF2a could promote a stress-resistant state as
part of integrated stress responses (ISR), but could also promote
apoptosis. It apparently correlates with apoptosis induction by TAIII
in breast cancer cells. In MDAMB231 cells, a much more robust
transcriptionalERstressresponseisseenthaninBT474cells(Table2)
indicating that the ER stress transcriptional program that should
follow eIF2a phosphorylation is not completed in BT474. We have
examined if salubrinal, a selective inhibitor of eIF2a de-phosphor-
ylation [39], can influence the outcome of TAIII treatment, but
salubrinal did not change the status of peIF2a or the extent of
apoptosis in any of the cell lines including BT474 (not shown),
indicating that dephosphorylation of eIF2a is not responsible for the
relative weakness of ER stress responses in BT474.
In turn, the weak ER stress response of BT474 could be
causative in the lack of induction of protective autophagy in these
cells, and their increased sensitivity to TAIII. In particular, the
lack of induction of GRP78 and a weak upregulation of ATF4
(Figure 5) in BT474 could contribute to lack of autophagy since
both these ER stress responders were shown to contribute to
autophagy [40,41]. It is also possible that the dual effects of TAIII
on mTORC1 and ER make different contributions to induction of
apoptosis versus protective autophagy in different cells. Our data
also suggest that lack of significant cytotoxic activity of TAIII
towards normal cells could be related to two notable differences in
their responses compared to cancer cells: first, lack of mTORC1
Figure 6. Autophagy induced by TAIII plays a protective role in cell
death. A. Inhibition of autophagy augments apoptosis induced by TAIII in
MDAMB231 and MCF10A cell lines, but not in BT474. Cells were pretreated
for three hours with 20 mM of chloroquine (CQ) after which TAIII (4 mMf o r
BT474, 5 mM for MM231 and 7.5 mM for MCF10A) was added for 24 hours. B.
A cartoon illustrating the various cellular effects of BN108 and TAIII. The
pathways induced selectively in cancer cells are shown in thicker lines.
doi:10.1371/journal.pone.0007283.g006
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nontransformed cells from TAIII (Figure 5D).
The role of the observed induction of SREBP-2 and its target
genes in TAIII cytotoxicity remains to be elucidated, though it is
unlikely to be directly relevant to cell death, because SREBP-2 is
induced in relatively resistant MCF10A cells. One possibility is
that TAIII induces specific changes in ER cholesterol levels rather
than large fluctuation in total cellular cholesterol. Even small
changes in ER cholesterol content can trigger changes in the
SREBP-2 status through activating protein SCAP and inhibitor
INSIG-1 [35]. The other intriguing possibility is based on the
described antagonism between integrated stress response (ISR) and
sterol-regulated gene expression in cells treated with selected ER
stress inducing compounds [42]. In MDAMB231 cells the ER
stress response is prominent (Table 2 and Figure 5) and SREBP
activation is less pronounced (Table 1), while in BT474 markers of
ER stress are either not induced or induced weakly (Table 2 and
Figure 5), but SREBP-2 activation is very strong (Table 1).
Harding et al. described this reciprocal relationship of the ISR and
sterol-regulated gene expression and showed its dependence on
eIF2a phosphorylation [42]. Perhaps more surprisingly, in this
work deletion of PERK, the only known ER stress responsive
kinase that phosphorylates eIF2a, did not lead to the abrogation of
eIF2a phosphorylation in cells treated with the compounds. We
show that even though PERK is not phosphorylated in BT474
cells treated with TAIII, eIF2a is phosphorylated. Therefore, in
BT474 cells a different mechanism, not involving PERK, might be
responsible for activation of eIF2a. There are recent evidence that
ER stress could induce phosphorylation of eIF2a by mechanisms
independent of PERK [43].
We have not observed induction of ROS that was recently
described in HeLa cells subjected to treatment with TAIII [4]. This
difference between our observations and the previously reported
results may stem from at least two potential sources: first, it could be
related to the different concentrations of TAIII used. In the paper
by Sy et al., [4], IC50 of TAIII was close to 10 mM for HeLa cells
after two day treatment, whereas the two breast cancer cell lines we
have used were significantly more sensitive, with IC50 values of
about 2.5 and 6 mM after 1 day. Second, and more important, the
relatively modest increase in cellular ROS (about 30–40% over
baseline) reported in HeLa cells [4] was observed between 24 to
48 hours of treatment with TAIII. We examined the effects of
BN108 and TAIII on mitochondria during the first 4–6 hours of
treatment with TAIII or BN108, and could not detect appreciable
induction of ROS or dissipation of the mitochondrial membrane
potential. At this time, however, inhibition of mTORC1 and
phosphorylationof eIF2a (Figures 3–5) wereevident, indicating that
these changes well precede the mitochondrial events. Mitochondrial
degeneration could play a role in the TAIII induced death, but it
would most likely occur as consequences of the other, described
here, events triggered by TAIII earlier.
It is potentially important for the understanding of the
mechanisms of TAIII cytotoxicity that both responses elicited by
it in tumor cells, i.e. inhibition of mTORC1 and ER stress, induce
autophagy [8,9,13]. TAIII induced autophagy is protective in both
tumor and normal cells, but the pro-apoptotic effects of the
mTORC1 inhibition and ER stress appear to prevail in tumor
cells. These results indicate that TAIII could be a promising
candidate for drug development as a selective anti-cancer agent.
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Figure S1 Activation of caspases 4 and 9 by BN108. Extracts
prepared fromBT474 treated with BN108 for indicated times were
analyzed for caspase-4 and caspase-9 activity using caspase activity
kits from BioVisionaccording to manufacturer’s instructions.
Caspase 4 inhibitor LEVD (EMD Biosciences) was used at 8 mM
to ensure the specificity of the assay.
Found at: doi:10.1371/journal.pone.0007283.s005 (0.07 MB
PDF)
Figure S2 Effects of BN108 and TAIII on cholesterol synthesis.
A. BT474 cells were treated for 4 hours with either 2.5 mM TAIII
or 0.5 mg/ml of BN108, and extracts were subjected to Western
blotting with antibodies to isopentenyl-diphosphate delta isomer-
ase (IDI-1) and ATP-citrate lyase (ACL), both transcriptional
targets of SREBP-2 . B. SREBP-2 is activated by BN108 in both
cancer and non-transformed cells. Time course of SREBP-2
activation in MDAMB231 and MCF10A cells treated with BN108
(0.5 mg/ml) for the times indicated. C. TAIII increases levels of
SREBP-2 target isopentenyl-diphosphate delta isomerase (IDI-1)
in both cancer and nontransformed cells. Cells were treated with
TAIII at 2.5 mM (BT474) and 5 mM (MCF10A). D. Total
cholesterol levels in MDAMB231 and MCF10A cells treated with
TAIII or BN108. E. TAIII increases levels of INSIG-1, inhibitor of
SREBP-2 activation. BT474 cells were treated with TAIII and
extracts blotted with anti-INSIG-1 antibody.
Found at: doi:10.1371/journal.pone.0007283.s006 (0.65 MB
PDF)
Figure S3 TAIII treatment induces autophagy. MDAMB231
cells were transfected with GFP-LC3 expressing construct and
subjected to treatment with 5 mM of TAIII for 16 hours. A.
Immunofluorescent detection of EGFP-LC3 in untreated (mock)
and treated cells. B. Western blot analysis of the same cells treated
with TAIII and detected with an antibody to LC3. Both GFP-
LC3-I and proteolytically cleaved EGFP-LC3-II are detected.
Endogenous LC3-I is not detected due to its low expression levels
or antibody preference for LC3-II.
Found at: doi:10.1371/journal.pone.0007283.s007 (0.09 MB
PDF)
Acknowledgments
We are grateful to Dr. Xioyue Zhao for the analysis of the expression array
results.
Author Contributions
Conceived and designed the experiments: FWK SF ES. Performed the
experiments: FWK SF CG MS RS YLZ ES. Analyzed the data: FWK SF
IC ES. Wrote the paper: ES.
Cytotoxic Selectivity of TAIII
PLoS ONE | www.plosone.org 11 September 2009 | Volume 4 | Issue 9 | e7283References
1. Kawasaki T, Yamauchi T (1963) Saponins of Timo (Anemarrhenae Rhizoma).
Ii. Structure of Timosaponin a-Iii. Chem Pharm Bull (Tokyo) 11: 1221–1224.
2. Saito S, Nagase S, Ichinose K (1994) New steroidal saponins from the rhizomes
of Anemarrhena asphodeloides Bunge (Liliaceae). Chem Pharm Bull (Tokyo) 42:
2342–2345.
3. Zhang J, Meng Z, Zhang M, Ma D, Xu S, et al. (1999) Effect of six steroidal
saponins isolated from anemarrhenae rhizoma on platelet aggregation and
hemolysis in human blood. Clin Chim Acta 289: 79–88.
4. Sy LK, Yan SC, Lok CN, Man RY, Che CM (2008) Timosaponin A-III induces
autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells.
Cancer Res 68: 10229–10237.
5. Mori K (2000) Tripartite management of unfolded proteins in the endoplasmic
reticulum. Cell 101: 451–454.
6. Ron D, Walter P (2007) Signal integration in the endoplasmic reticulum
unfolded protein response. Nat Rev Mol Cell Biol 8: 519–529.
7. Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, et al. (2004)
Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and
Abeta-induced cell death. J Cell Biol 165: 347–356.
8. Hoyer-Hansen M, Jaattela M (2007) Connecting endoplasmic reticulum stress to
autophagy by unfolded protein response and calcium. Cell Death Differ 14:
1576–1582.
9. Yorimitsu T, Klionsky DJ (2007) Endoplasmic reticulum stress: a new pathway
to induce autophagy. Autophagy 3: 160–162.
10. Gozuacik D, Kimchi A (2007) Autophagy and cell death. Curr Top Dev Biol 78:
217–245.
11. Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in
cancer development and response to therapy. Nat Rev Cancer 5: 726–734.
12. Levine B, Yuan J (2005) Autophagy in cell death: an innocent convict? J Clin
Invest 115: 2679–2688.
13. Diaz-Troya S, Perez-Perez ME, Florencio FJ, Crespo JL (2008) The role of
TOR in autophagy regulation from yeast to plants and mammals. Autophagy 4:
851–865.
14. Proud CG (2009) mTORC1 signalling and mRNA translation. Biochem Soc
Trans 37: 227–231.
15. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship.
Nat Rev Cancer 6: 729–734.
16. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. (2006) Prolonged
rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:
159–168.
17. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, et al. (2004) Mammalian
TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.
Nat Cell Biol 6: 1122–1128.
18. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, et al. (2004) Rictor, a
novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-
independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296–1302.
19. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, et al. (2009) Active-site
inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and
mTORC2. PLoS Biol 7: e38.
20. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, et al. (2009) An ATP-
competitive mammalian target of rapamycin inhibitor reveals rapamycin-
resistant functions of mTORC1. J Biol Chem 284: 8023–8032.
21. Shoemaker M, Hamilton B, Dairkee SH, Cohen I, Campbell MJ (2005) In vitro
anticancer activity of twelve Chinese medicinal herbs. Phytother Res 19:
649–651.
22. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, et al. (2002)
REDD1, a developmentally regulated transcriptional target of p63 and p53,
links p63 to regulation of reactive oxygen species. Mol Cell 10: 995–1005.
23. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, et al. (2002) Identification of
a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in
apoptosis. Mol Cell Biol 22: 2283–2293.
24. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, et al. (2004)
Regulation of mTOR function in response to hypoxia by REDD1 and the
TSC1/TSC2 tumor suppressor complex. Genes Dev 18: 2893–2904.
25. Corradetti MN, Inoki K, Guan KL (2005) The stress-inducted proteins RTP801
and RTP801L are negative regulators of the mammalian target of rapamycin
pathway. J Biol Chem 280: 9769–9772.
26. Reiling JH, Hafen E (2004) The hypoxia-induced paralogs Scylla and Charybdis
inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila.
Genes Dev 18: 2879–2892.
27. Skeen JE, Bhaskar PT, Chen CC, Chen WS, Peng XD, et al. (2006) Akt
deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-
independent and mTORC1-dependent manner. Cancer Cell 10: 269–280.
28. Copp J, Manning G, Hunter T (2009) TORC-specific phosphorylation of
mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for
intact mTOR signaling complex 2. Cancer Res 69: 1821–1827.
29. Audas TE, Li Y, Liang G, Lu R (2008) A novel protein, Luman/CREB3
recruitment factor, inhibits Luman activation of the unfolded protein response.
Mol Cell Biol 28: 3952–3966.
30. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: transcriptional mediators
of lipid homeostasis. Cold Spring Harb Symp Quant Biol 67: 491–498.
31. Colgan SM, Tang D, Werstuck GH, Austin RC (2007) Endoplasmic reticulum
stress causes the activation of sterol regulatory element binding protein-2.
Int J Biochem Cell Biol 39: 1843–1851.
32. Kovacs WJ, Tape KN, Shackelford JE, Wikander TM, Richards MJ, et al.
(2008) Peroxisome deficiency causes a complex phenotype due to hepatic
SREBP/Insig dysregulation associated with endoplasmic reticulum stress. J Biol
Chem.
33. Lee JN, Ye J (2004) Proteolytic activation of sterol regulatory element-binding
protein induced by cellular stress through depletion of Insig-1. J Biol Chem 279:
45257–45265.
34. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, et al. (2001)
Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the
cholesterol and triglyceride biosynthetic pathways. J Clin Invest 107: 1263–1273.
35. Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS (2008) Switch-like
control of SREBP-2 transport triggered by small changes in ER cholesterol: a
delicate balance. Cell Metab 8: 512–521.
36. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, et al. (2002) Crucial step
in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a
membrane protein that facilitates retention of SREBPs in ER. Cell 110:
489–500.
37. Rao RV, Peel A, Logvinova A, del Rio G, Hermel E, et al. (2002) Coupling
endoplasmic reticulum stress to the cell death program: role of the ER
chaperone GRP78. FEBS Lett 514: 122–128.
38. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, et al. (2003)
Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis
induced by topoisomerase inhibitors: role of ATP binding site in suppression of
caspase-7 activation. J Biol Chem 278: 20915–20924.
39. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, et al. (2005) A selective
inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science
307: 935–939.
40. Li J, Ni M, Lee B, Barron E, Hinton DR, et al. (2008) The unfolded protein
response regulator GRP78/BiP is required for endoplasmic reticulum integrity
and stress-induced autophagy in mammalian cells. Cell Death Differ 15:
1460–1471.
41. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, et al. (2009) The role of
ATF4 stabilization and autophagy in resistance of breast cancer cells treated
with Bortezomib. Cancer Res 69: 4415–4423.
42. Harding HP, Zhang Y, Khersonsky S, Marciniak S, Scheuner D, et al. (2005)
Bioactive small molecules reveal antagonism between the integrated stress
response and sterol-regulated gene expression. Cell Metab 2: 361–371.
43. Carra S, Brunsting JF, Lambert H, Landry J, Kampinga HH (2009) HspB8
participates in protein quality control by a non-chaperone-like mechanism that
requires eIF2{alpha} phosphorylation. J Biol Chem 284: 5523–5532.
Cytotoxic Selectivity of TAIII
PLoS ONE | www.plosone.org 12 September 2009 | Volume 4 | Issue 9 | e7283